New trial
Phase 3 Study of BGB-16673, a BTK protein degrader, in CLL/SLL patients.
- Trial ID
- NCT06846671 on ClinicalTrials.gov
- Cancer type
- CLL/SLL
- Location
- 101 Locations
- Published in
- New in Oncology - June 16, 2025
This study compares BGB-16673 monotherapy against investigator's choice regimens (idelalisib plus rituximab, bendamustine plus rituximab, or venetoclax plus rituximab retreatment) in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with BTK and BCL2 inhibitors. Conducted by BeiGene across multiple international sites, it aims to evaluate efficacy and safety in a 2nd line+ setting.
More in chronic lymphocytic leukemia
-
New trial · Oct 22, 2026 · NCT07847957
Phase 1b/2 roginolisib PI3K-delta inhibitor with sequential obinutuzumab and venetoclax after BTK inhibitors in CLL -
Trial result · Oct 15, 2026 · NCT03462719
Ibrutinib (BTK inhibitor) + venetoclax (BCL-2 inhibitor) improves long-term OS/PFS in 1L CLL, with more progression-free time without grade 3/4 AEs -
Trial result · Oct 15, 2026 · NCT03900598
Safimaltib (JNJ-67856633) MALT1 inhibitor posts 28.8% pooled ORR across heavily pretreated B-cell lymphomas and CLL, with frequent hyperbilirubinemia -
New trial · Oct 15, 2026 · NCT07516093
Phase 3 DAYBreak CLL-306 compares bexobrutideg BTK degradation with pirtobrutinib after covalent BTK inhibition -
New trial · Oct 15, 2026 · NCT07819214
Phase 2 epcoritamab CD3×CD20 consolidation seeks deeper remissions after at least 6 months of BTK inhibition in high-risk CLL